Crossmark

A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer

Crossref DOI link: https://doi.org/10.1007/s00280-016-3108-5

Published Online: 2016-07-23

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beg, Muhammad S.

Azad, Nilofer S.

Patel, Sandip P.

Torrealba, Jose

Mavroukakis, Sharon

Beatson, Melony A.

Wang, Xue Ping

Arlen, Philip M.

Morse, Michael A.
Funding

Funding for this research was provided by:

Precision Biologics Inc
License Information

License valid from 2016-07-23